Horizon Therapeutics

Dublin, Ireland Founded: 2008 • Age: 18 yrs Acquired By Amgen
Developer of drugs for treating rare and autoimmune diseases
Request Access

About Horizon Therapeutics

Horizon Therapeutics is a company based in Dublin (Ireland) founded in 2008 was acquired by Amgen in December 2022.. Horizon Therapeutics has raised $61.78 million across 7 funding rounds from investors including Amgen. Horizon Therapeutics has completed 5 acquisitions, including Crealta Pharmaceuticals, Nitec Pharma and Raptor Pharma. Horizon Therapeutics offers products and services including Biologic Medicines, DNA Encoded Libraries, and ATOMIC Model. Horizon Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Forge Biologics, among others.

  • Headquarter Dublin, Ireland
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Amgen Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $617.41 M
    14
    as on Dec 31, 2022
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $61.78 M (USD)

    in 7 rounds

  • Latest Funding Round
    $69.4 M (USD), Post-IPO

    Oct 01, 2014

  • Investors
  • Employee Count
    Employee Count
  • Investments & Acquisitions
  • Acquired by
    Amgen

    (Dec 12, 2022)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Horizon Therapeutics

Horizon Therapeutics offers a comprehensive portfolio of products and services, including Biologic Medicines, DNA Encoded Libraries, and ATOMIC Model. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Treatments for serious diseases using biologic agents

Platform for screening compounds in drug design

Machine learning for accelerating clinical trials

People of Horizon Therapeutics
Headcount 10000+
Employee Profiles 1061
Board Members and Advisors 47
Employee Profiles
People
Shambhavi Sharma
Manager, Commercial Analytics
People
Murdo Gordon
EVP, Global Commercial Operations
People
Tairn Pales
Senior Manager, Global Strategic Sourcing, Commercial Operations
People
Siyabonga Makhanya
Sr. Associate QA (validation / Packaging / PASX Master Data)

Unlock access to complete

Board Members and Advisors
people
Ellen J. Kullman
Director
people
Amy E. Miles
Director
people
Tyler Jacks
Director
people
S. Omar Ishrak
Director

Unlock access to complete

Funding Insights of Horizon Therapeutics

Horizon Therapeutics has successfully raised a total of $61.78M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $69.4 million completed in October 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 7
  • Last Round Post-IPO — $69.4M
  • First Round

    (28 Oct 2008)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2014 Amount Post-IPO - Horizon Therapeutics Valuation

investors

Nov, 2013 Amount Post-IPO - Horizon Therapeutics Valuation

investors

Mar, 2012 Amount Post-IPO - Horizon Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Horizon Therapeutics

Horizon Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Amgen. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Developer of pharmaceutical products for treating multiple diseases
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Horizon Therapeutics

Horizon Therapeutics has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Crealta Pharmaceuticals, Nitec Pharma and Raptor Pharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Developer of biologics for treating severe inflammation and autoimmune diseases
2017
Biologic medicines are developed and manufactured for serious illnesses.
2013
Developer of protein based therapeutics for the treatment of chronic granulomatous disease and malignant osteopetrosis
2011
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Horizon Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Horizon Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Horizon Therapeutics

Horizon Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Forge Biologics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Therapeutics for genetic diseases are developed through targeted interventions.
domain founded_year HQ Location
Gene therapies for rare diseases including retinal dystrophies are developed.
domain founded_year HQ Location
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
domain founded_year HQ Location
Gene therapies for rare diseases are developed to treat patients.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Horizon Therapeutics

Frequently Asked Questions about Horizon Therapeutics

When was Horizon Therapeutics founded?

Horizon Therapeutics was founded in 2008.

Where is Horizon Therapeutics located?

Horizon Therapeutics is headquartered in Dublin, Ireland.

Who is the current CEO of Horizon Therapeutics?

Timothy Walbert is the current CEO of Horizon Therapeutics.

Is Horizon Therapeutics a funded company?

Horizon Therapeutics is a funded company, having raised a total of $61.78M across 7 funding rounds to date. The company's 1st funding round was a Post-IPO of $65.93M, raised on Oct 28, 2008.

What is the annual revenue of Horizon Therapeutics?

Annual revenue of Horizon Therapeutics is $617.41M as on Dec 31, 2022.

What does Horizon Therapeutics do?

Developer of drugs for treating rare and autoimmune diseases. The lead candidates of the company are UPLIZNA fucosylated IgG 1 kappa (IgG1κ) monoclonal antibodies for myasthenia gravis, HZN-825 for idiopathic pulmonary fibrosis, and HZN-4920 for focal segmental glomerulosclerosis as well as kidney transplant rejection, rheumatoid arthritis, and Sjogrens syndrome.

Who are the top competitors of Horizon Therapeutics?

Horizon Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.

What products or services does Horizon Therapeutics offer?

Horizon Therapeutics offers Biologic Medicines, DNA Encoded Libraries, and ATOMIC Model.

How many acquisitions has Horizon Therapeutics made?

Horizon Therapeutics has made 5 acquisitions, including Crealta Pharmaceuticals, Nitec Pharma, and Raptor Pharma.

Who are Horizon Therapeutics's investors?

Horizon Therapeutics has 1 investor. Key investors include Amgen.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available